Self-amplified activatable nanophotosensitizers for HIF-1α inhibition-enhanced photodynamic therapy

Guo, Zixin; Wang, Nana; He, Xiaowen; Shen, Jinlong; Yang, Xiangqi; Xie, Chen; Fan, Quli; Zhou, Wen

doi:10.1039/d3nr05245a

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, activatable PSs represent an alternative strategy to enhance PDT selectivity [ 26 , 27 ]. These PSs are initially inactive but become active upon encountering endogenous stimuli specific to tumors, such as elevated levels of glutathione (GSH) [ 28 , 29 , 30 ] and hydrogen peroxide [ 31 , 32 ], overexpressing enzymes [ 33 , 34 , 35 , 36 , 37 ], as well as a weak acidic environment [ 38 , 39 , 40 ].…”

Section: Introductionmentioning

confidence: 99%

A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer

Wu,

Luo,

Zhu

et al. 2024

IJMS

View full text Add to dashboard Cite

Photodynamic Therapy (PDT) is recognized for its exceptional effectiveness as a promising cancer treatment method. However, it is noted that overexposure to the dosage and sunlight in traditional PDT can result in damage to healthy tissues, due to the low tumor selectivity of currently available photosensitizers (PSs). To address this challenge, we introduce herein a new strategy where the small molecule-targeted agent, erlotinib, is integrated into a boron dipyrromethene (BODIPY)-based PS to form conjugate 6 to enhance the precision of PDT. This conjugate demonstrates optical absorption, fluorescence emission, and singlet oxygen generation efficiency comparable to the reference compound 7, which lacks erlotinib. In vitro studies reveal that, after internalization, conjugate 6 predominantly accumulates in the lysosomes of HepG2 cells, exhibiting significant photocytotoxicity with an IC50 value of 3.01 µM. A distinct preference for HepG2 cells over HELF cells is observed with conjugate 6 but not with compound 7. In vivo experiments further confirm that conjugate 6 has a specific affinity for tumor tissues, and the combination treatment of conjugate 6 with laser illumination can effectively eradicate H22 tumors in mice with outstanding biosafety. This study presents a novel and potential PS for achieving precise PDT against cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer

Wu,

Luo,

Zhu

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Self-amplified activatable nanophotosensitizers for HIF-1α inhibition-enhanced photodynamic therapy

Abstract: Activatable photodynamic therapy (PDT) has shown great potential in cancer therapy owing to its high tumor specificity and minimized side effect. However, the relatively low level of biomarkers within tumor...

Cited by 1 publication

References 32 publications

A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer

A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer

Contact Info

Product

Resources

About